Figure 2From: Cost-effectiveness of ranibizumab for neovascular age-related macular degenerationIncremental costs versus time for ranibizumab treatment compared with no ranibizumab treatment, assuming the base-case scenario and the wholesale price for ranibizumab, and including caregiver costs.Back to article page